On June 12, 2025, Hepion Pharmaceuticals held its Annual Meeting where stockholders voted on four proposals, including director elections and a potential reverse stock split ranging from 1-for-5 to 1-for-20, which received mixed support (only 38% approval). The company's independent auditors were ratified and executive compensation was also approved on an advisory basis.